<DOC>
	<DOCNO>NCT02274961</DOCNO>
	<brief_summary>This clinical study hypothesize S-pantoprazole 10mg would effective treat Non erosive Reflux Disease placebo .</brief_summary>
	<brief_title>S-pantoprazole 10mg Phase III Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Adults age 19 75 inclusive Patient history heartburn acid regurgitation least 3 month . Those episode heartburn 2 day last 7 day prior baseline Patients negative erosive esophagitis confirm esophagogastroduodenoscopy ( EGD ) perform within 7 day screen Capable provide write informed consent , willing able comply procedure study History endoscopic erosive esophagitis ( EE ) screen EGD . Historical evidence follow disease/conditions : symptom Irritable bowel syndrome More tha 3cm endoscopic Barrett 's esophagus significant dysplastic change esophagus Proton Pump Inhibitor ( PPI ) within 4 week prior baseline visit H2receptor antagonist , sucralfate , prokinetics , Non Steroidal Antiinflammatory Drugs ( NSAIDs ) ( except low dose aspirin ) 2 week prior screen Historical evidence follow disease/conditions 3 month : ZollingerEllison syndrome , primary esophageal motility disorder achalasia , esophageal stricture , pancreatitis , gastric ulcer , evidence upper G.I . malignancy , pancreatitis , malabsorption , severe cardiovascular pulmonary disease , severe liver disease , severe renal disease , cerebral vascular disease , Known hypersensitivity component drug pregnancy lactation ( F )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>